ATE201905T1 - Acethylhydrolase des plättchen aktivierenden faktors - Google Patents

Acethylhydrolase des plättchen aktivierenden faktors

Info

Publication number
ATE201905T1
ATE201905T1 AT94930623T AT94930623T ATE201905T1 AT E201905 T1 ATE201905 T1 AT E201905T1 AT 94930623 T AT94930623 T AT 94930623T AT 94930623 T AT94930623 T AT 94930623T AT E201905 T1 ATE201905 T1 AT E201905T1
Authority
AT
Austria
Prior art keywords
platele
acethyl
hydrolase
activate factor
activating factor
Prior art date
Application number
AT94930623T
Other languages
English (en)
Inventor
Laurence S Cousens
Christine D Eberhardt
Patrick Gray
Trong Hai Le
Larry W Tjoelker
Cheryl L Wilder
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of ATE201905T1 publication Critical patent/ATE201905T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
AT94930623T 1993-10-06 1994-10-06 Acethylhydrolase des plättchen aktivierenden faktors ATE201905T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13380393A 1993-10-06 1993-10-06
PCT/US1994/011340 WO1995009921A1 (en) 1993-10-06 1994-10-06 Platelet-activating factor acetylhydrolase

Publications (1)

Publication Number Publication Date
ATE201905T1 true ATE201905T1 (de) 2001-06-15

Family

ID=22460373

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00128728T ATE315655T1 (de) 1993-10-06 1994-10-06 Acethylhydrolase des plättchen aktivierenden faktors
AT94930623T ATE201905T1 (de) 1993-10-06 1994-10-06 Acethylhydrolase des plättchen aktivierenden faktors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00128728T ATE315655T1 (de) 1993-10-06 1994-10-06 Acethylhydrolase des plättchen aktivierenden faktors

Country Status (11)

Country Link
US (5) US5641669A (de)
EP (3) EP1634953A3 (de)
JP (3) JP3613398B2 (de)
AT (2) ATE315655T1 (de)
CA (1) CA2151045C (de)
DE (2) DE69427392T2 (de)
DK (2) DK1096016T3 (de)
ES (2) ES2258955T3 (de)
GR (1) GR3036535T3 (de)
PT (1) PT673426E (de)
WO (1) WO1995009921A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
JP3563091B2 (ja) * 1993-08-03 2004-09-08 第一サントリーファーマ株式会社 酸化リン脂質分解酵素およびその遺伝子
US6146625A (en) * 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
JP2002515728A (ja) * 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規用途
JPH11514228A (ja) * 1995-09-29 1999-12-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポ蛋白結合ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）ＰＡＦアセチルヒドロラーゼに対して配列相同性を有する化合物
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
US6166292A (en) * 1996-04-26 2000-12-26 Ajinomoto Co., Inc. Raffinose synthetase gene, method of producing raffinose and transgenic plant
US6891084B1 (en) * 1996-04-26 2005-05-10 Ajinomoto Co., Inc. DNA encoding raffinose synthase from soybean
JPH1017600A (ja) * 1996-06-28 1998-01-20 Suntory Ltd 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子
BR9711882A (pt) * 1997-08-13 1999-09-21 Icos Corp Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf.
JP2002528084A (ja) * 1998-10-28 2002-09-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 固定化金属アフィニティークロマトグラフィーを用いる低密度リポタンパク質関連ホスホリパーゼａ２の精製方法
GB9923790D0 (en) * 1999-10-08 1999-12-08 Isis Innovation Immunoregulatory compositions
NZ520752A (en) 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
US7468266B2 (en) * 2001-05-30 2008-12-23 Ryogen, Llc Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
US7475248B2 (en) 2002-04-29 2009-01-06 International Business Machines Corporation Enhanced message security
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
PL1633864T3 (pl) 2003-05-28 2010-09-30 Glaxo Group Ltd Wysokowydajny test aktywności Lp-PLA2
JP5155564B2 (ja) 2004-02-03 2013-03-06 ディアデクサス インコーポレーテッド Ｌｐ−ＰＬＡ２活性を検出する方法
US20070166777A1 (en) * 2004-04-16 2007-07-19 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP2007145814A (ja) * 2005-10-28 2007-06-14 Bizen Chemical Co Ltd 血小板活性化因子受容体拮抗剤および組成物
JP2009534035A (ja) * 2006-04-21 2009-09-24 ワイス 細胞系のハイスループットスクリーニング方法
EP2977452A3 (de) 2007-05-11 2016-05-25 Thomas Jefferson University Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen und störungen
CN101687009A (zh) 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
US8257697B2 (en) * 2007-10-31 2012-09-04 Allertech Laboratory Inc. Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
JP2009005705A (ja) * 2008-07-02 2009-01-15 Icos Corp 血小板活性化因子アセチルヒドロラーゼ
JP5596964B2 (ja) * 2008-12-02 2014-09-24 協和メデックス株式会社 リポ蛋白中成分の分別定量用標準品の製造方法
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
CN105542010B (zh) * 2015-12-31 2020-11-03 武汉华美生物工程有限公司 脂蛋白相关磷脂酶a2单克隆抗体、抗体对及制备方法、用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
GB9400413D0 (en) 1994-01-11 1994-03-09 Smithkline Beecham Plc Compounds
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
GB9313144D0 (en) 1993-06-25 1993-08-11 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
GR3036535T3 (en) 2001-12-31
JP2004129671A (ja) 2004-04-30
US5532152A (en) 1996-07-02
JP2006056901A (ja) 2006-03-02
DE69427392D1 (de) 2001-07-12
ES2159573T3 (es) 2001-10-16
ATE315655T1 (de) 2006-02-15
WO1995009921A1 (en) 1995-04-13
EP1634953A3 (de) 2006-06-28
JP3759941B2 (ja) 2006-03-29
US5605801A (en) 1997-02-25
DK1096016T3 (da) 2006-05-29
HK1038587A1 (en) 2002-03-22
DE69434609T2 (de) 2006-09-21
DE69434609D1 (de) 2006-04-06
EP0673426B1 (de) 2001-06-06
ES2258955T3 (es) 2006-09-16
HK1012023A1 (en) 1999-07-23
CA2151045A1 (en) 1995-04-13
US5641669A (en) 1997-06-24
EP1634953A2 (de) 2006-03-15
DE69427392T2 (de) 2002-05-23
CA2151045C (en) 2002-04-30
EP1096016B1 (de) 2006-01-11
JPH08504603A (ja) 1996-05-21
JP3613398B2 (ja) 2005-01-26
EP0673426A1 (de) 1995-09-27
PT673426E (pt) 2001-11-30
US20050100540A1 (en) 2005-05-12
DK0673426T3 (da) 2001-08-27
EP1096016A1 (de) 2001-05-02
US5698403A (en) 1997-12-16

Similar Documents

Publication Publication Date Title
ATE315655T1 (de) Acethylhydrolase des plättchen aktivierenden faktors
HU9203074D0 (en) 2-substituted indene-2-mercapto-acetamide being inhibitors of encefalinase and ace
IL99769A0 (en) Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
HU9203075D0 (en) 2-substituted indene-2-carboxi-alkyl derivatives being inhibitors of encefalinase and ace
DE69626324D1 (de) Prozess zur verminderung des säuregehaltes und der korrosivität von rohöl
DK1029921T3 (da) Serpinresistent t-PA, mutanter, gener
BR9107258A (pt) Protease mutante e processo compreendendo o tratamento de uma protease
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
DE69411692D1 (de) Mittel zur Förderung der Proliferationen von Bifidobacterium
DE69330807D1 (de) Verfahren zur Herstellung von gereinigtem Enzym
MX9305784A (es) N-(aceilaminometil) glutaril amino acidos.
BG101832A (en) Methods and materials for attributing plant resistance to diseases
WO1996024650A3 (en) Cytoplasmic antiproteinase-2 and cytoplasmic antiproteinase-3 and coding sequences
IL106748A0 (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
CA2267994A1 (en) Truncated platelet-activating factor acetylhydrolase
IT9021986A0 (it) Procedimento e mezzi per la produzione continua di corpi di carbone
ES2095233T3 (es) Produccion eficaz de proteasa mutante.
DE69426008D1 (de) Verfahren zur Gewinnung von einzelnen Mikroorganismen und Anwendungen dieses Verfahrens
PL341071A1 (en) Method of obtaining cleistogamouic mutants of hybridized plants
IL101743A0 (en) 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
DE69427794D1 (de) Verbesserungen an Erdmühlen zur Herstellung von Terrakotta-Produkten
DE69401515D1 (de) Verfahren zur verbesserung des mahlens von rohmaterialien
GB2288398B (en) Monomeric and oligomeric bisphenyl-HALS phosphites as stabilizers
ITVI930098A1 (it) Ciclo di lavorazione per la produzione di pelli tipo nabuk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification